Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Saturday. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners cut their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Trading Down 2.7 %

AWH opened at $0.73 on Friday. The firm has a 50 day moving average of $0.83 and a two-hundred day moving average of $1.16. The firm has a market capitalization of $12.17 million, a PE ratio of -0.61 and a beta of 1.39. Aspira Women’s Health has a 12-month low of $0.67 and a 12-month high of $5.65.

Institutional Trading of Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is owned by institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.